BCL2 gene abnormality and PI status of adults with follicular lymphomas (cohort 2)
| . | BCL2-N HPI (n = 13) . | BCL2-R HPI* (n = 8) . | BCL2-N LPI (n = 12) . | BCL2-R LPI (n = 25) . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 37 (18-61) | 60 (32-81) | 65 (39-82) | 61 (31-80) | .002 |
| Stage I | 13/13 (100) | 2/7 (28) | 5/12 (42) | 8/22 (36) | .001 |
| Treated with chemotherapy | 7/9 (78) | 5/7 (71) | 8/12 (67) | 16/22 (73) | .96 |
| Relapse or progression | 0/13 (0) | 5/8 (63) | 10/12 (83) | 21/24 (88) | < .0001 |
| Persistent disease at latest follow-up | 0/13 (0) | 5/8 (63) | 8/12 (67) | 18/25 (72) | .0002 |
| Median follow-up, mo (range) | 61 (1-187) | 36 (6-242) | 107 (52-217) | 119 (31-218) | .05 |
| . | BCL2-N HPI (n = 13) . | BCL2-R HPI* (n = 8) . | BCL2-N LPI (n = 12) . | BCL2-R LPI (n = 25) . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 37 (18-61) | 60 (32-81) | 65 (39-82) | 61 (31-80) | .002 |
| Stage I | 13/13 (100) | 2/7 (28) | 5/12 (42) | 8/22 (36) | .001 |
| Treated with chemotherapy | 7/9 (78) | 5/7 (71) | 8/12 (67) | 16/22 (73) | .96 |
| Relapse or progression | 0/13 (0) | 5/8 (63) | 10/12 (83) | 21/24 (88) | < .0001 |
| Persistent disease at latest follow-up | 0/13 (0) | 5/8 (63) | 8/12 (67) | 18/25 (72) | .0002 |
| Median follow-up, mo (range) | 61 (1-187) | 36 (6-242) | 107 (52-217) | 119 (31-218) | .05 |
Values are no. (%) unless otherwise noted.
BCL2-N indicates no BCL2 gene abnormality by FISH; BCL2-R, BCL2 gene rearrangement or gain by FISH; HPI, high (> 30%) Ki67 proliferation index; LPI: low (< 30%) Ki67 proliferation index.
Includes 1 case with 1 extra copy of BCL2 gene by FISH and strong BCL2 expression, as demonstrated by IHC.